当前位置: 首页 > 期刊 > 《中国实用医药》 > 202024
编号:13816348
不同方案诱导化疗联合同期放化疗治疗局部晚期鼻咽癌的近期疗效及安全性分析(4)
http://www.100md.com 2020年8月25日 《中国实用医药》 202024
     [11] Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase Ⅲ multicentre randomised controlled trial. European Journal of Cancer, 2017, 75(2):14-23.

    [12] Chen YP, Tang LL, Yang Q, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clinical Cancer Research, 2018, 24(8):1824-1833.

    [13] Peng H, Tang LL, Chen BB, et al. Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis. Oral Oncology, 2018, 79(2):40-46.

    [14] 劉婷, 段爱雄, 韩光锋. 紫杉醇联合奈达铂诱导化疗后同步放化疗治疗局部晚期鼻咽癌52例. 安徽医药, 2019, 23(4):823-826, 850.

    [15] 曾培容, 冯惠霞, 熊军义. TPF、PF方案诱导化疗联合同期放化疗治疗局部晚期鼻咽癌近期疗效比较. 中西医结合心血管病电子杂志, 2017, 5(24):37-38.

    [收稿日期:2020-06-24], 百拇医药(郭伟伟 赵玉华 郑剑霄 孔怡琳 詹文婷 李工)
上一页1 2 3 4